Clinical trials: Giant Cells Arteritis
Giant Cell Arteritis, Polymyalgia Rheumatica
DANIsh VASculitis Database (DANIVAS)
The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and…
- Trial name
- DANIVAS (NCT05935709)
- Where
- 2 sites in Denmark
- Volunteers
- 3,000 people
- Sponsor
- Aarhus University Hospital
Rheumatoid Arthritis, Psoriatic Arthritis
COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- NCT04335747
- Testing
- COVID-19 infection
- Where
- Denmark
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Salome Kristensen
Giant Cell Arteritis
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA).
- Trial name
- NCT03244709
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Hospital of Prato
Giant Cell Arteritis (GCA)
Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)
B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. Until now, it has not been possible to directly study these cells in living patients (essential to assess…
- Trial name
- RituxiMAP GCA (NCT07269938)
- Testing
- Zirconium Zr 89 labelled rituximab
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Giant Cell Arteritis (GCA)
The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant Cell Arteritis.
Giant cell arteritis (GCA) is the most common vasculitis in the elderly and is usually treated with long-term corticosteroid therapy. Many patients experience relapses and treatment-related side effects.
- Trial name
- NCT07246577
- Where
- Sweden
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Giant Cell Arteritis, Vasculitis
Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy
Temporal artery biopsy is a useful tool helping to the diagnosis of giant cell arteritis. However, other diagnoses might be associated with abnormal temporal artery biopsy.
- Trial name
- NCT04554290
- Testing
- temporal artery biopsy
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Central Hospital, Nancy, France
Horton's Disease
Study of the T CD8 Immune Response in Horton's Disease
The research hypothesis is that T lymphocytes CD8 play a role in the physiopathology of Horton's disease. At the inclusion visit, patients will have, as is the case in the usual strategy: A complete clinical examination carried…
- Trial name
- Horton CD8 (NCT02158208)
- Testing
- Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment, 16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment, Blood sample drawn into a 5 mL dry tube
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
Giant Cell Arteritis: Improving Use of Ultrasound Evaluation
Giant cell arteritis (GCA) is an inflammatory disease causing new, unaccustomed headache in the elderly and which can lead to blindness in 20-30% of untreated cases.
- Trial name
- GAULT (NCT02523625)
- Testing
- Ultrasound of temporal and axillary arteries
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Temporal Arteritis
Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis
Giant cell arteritis (GCA), also known as temporal arteritis, is a disease that usually only occurs in older adults. GCA causes inflammation of blood vessels, or vasculitis.
- Trial name
- NCT00315497
- Where
- 9 sites in United States, Canada
- Volunteers
- 426 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis, Polymyalgia Rheumatica
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT04102930
- Where
- 76 sites in United Kingdom
- Volunteers
- 4,500 people
- Sponsor
- University of Leeds
Giant Cell Arteritis
Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant cell arteritis (GCA or temporal arteritis or cranial arteritis) or Horton disease is a vasculitis that occurs in older adults, affecting vessels of medium and large caliber.
- Trial name
- ECHORTON (NCT02703922)
- Testing
- color Doppler ultrasound and TAB in case of CDU negative
- Where
- 6 sites in France
- Volunteers
- 165 people
- Sponsor
- Poitiers University Hospital
Horton Disease
Study of T Lymphocytes in Patients With Horton Disease
Giant-cell arteritis (GCA) is the most frequent vasculitis after 50 years. Corticosteroid therapy is the reference treatment for GCA.
- Trial name
- GAMAIT (NCT03313102)
- Testing
- blood samples
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis (GCA), Cardiovascular Diseases
TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients
This nationwide observational study emulates a target trial to compare the effect of tocilizumab versus methotrexate initiation on major adverse cardiovascular events (MACE) in patients with incident giant cell arteritis using…
- Trial name
- TACTIC-GCA (NCT07459335)
- Where
- 2 sites in France
- Volunteers
- 1,667 people
- Sponsor
- Groupe français d'étude des Maladies Inflammatoires de loeil
Giant Cell Arteritis
Abatacept for the Treatment of Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to…
- Trial name
- NCT04474847
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Giant Cell Arteritis (GCA)
Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
Giant cell arteritis is a vasculitis, i.e. inflammation of the artery walls, which generally affects people over the age of 50. Diagnosis can be long and difficult, as the clinical signs are not specific (headache, pain in the…
- Trial name
- QuickDx-GCA (NCT06742671)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Giant Cell Arteritis, Polymyalgia Rheumatica
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v.
- Trial name
- NCT06130540
- Testing
- Secukinumab
- Where
- 19 sites in United States, Czechia and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Giant Cell Arteritis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).
- Trial name
- NCT03923738
- Testing
- Tocilizumab
- Where
- 2 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Giant Cell Arteritis, Vasculitis
FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis
Giant cell arteritis (GCA) causes inflammation of the arteries and can lead to serious complications such as blindness, necessitating rapid diagnosis and treatment.
- Trial name
- NCT05000138
- Testing
- FDG PET/CT
- Where
- 5 sites in Canada, France and 1 more
- Volunteers
- 92 people
- Sponsor
- Jewish General Hospital
Giant Cell Arteritis
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
It has been reported that around 40% of GCA patients are able to decrease the prednisone dose until 0.1 mg/Kg/d or less after 6 months of treatment.
- Trial name
- HORTOCI (NCT01910038)
- Testing
- corticoids+ tocilizumab 8mg/Kg/4 weeks
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis, Large Vessel Giant Cell Arteriitis
Longitudinal Imaging in Patients With Large Vessel Vasculitis to Predict Further Disease Course
Longitudinal imaging in patients with large vessel vasculitis to predict further disease course
- Trial name
- NCT04204876
- Testing
- Magnet Resonance Imaging (MRI), PET/CT analysis
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University Hospital, Basel, Switzerland